VG Plastic Surgery
| Corea del Sud | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $145,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $75,000 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $55,000 | da $36,000 | da $140,000 |
Il medico è uno specialista leader nel trattamento del cancro al seno, con un'ampia formazione ed esperienza. Ha completato la sua formazione e tirocinio presso il Centro Medico dell'Università Yonsei in Corea del Sud e ha lavorato come chirurgo presso il Centro Tumori Yonsei.<\/p>
Dal 2011 al 2013, ha servito come professore consulente nel dipartimento di cancro al seno presso l'Università di Anderson negli Stati Uniti. La sua ricerca si concentra sul trattamento del cancro al seno utilizzando farmaci ormonali e chemioterapici.<\/p>
Il medico è membro dell'Associazione Medica Coreana, della Società Americana di Oncologia Clinica e dell'Associazione Americana per la Ricerca sul Cancro.<\/p>
Il medico è un pediatra ed ematologo specializzato nel trattamento della leucemia e dell'anemia aplastica. È esperto nell'esecuzione di trapianti di midollo osseo per bambini. Il medico ha completato i suoi studi presso la Seoul National University e ha acquisito esperienza come Professore Assistente nel Dipartimento di Pediatria del Samsung Medical Center. Ha approfondito la sua esperienza come Ricercatore presso l'Università dell'Indiana. Dal 2011, contribuisce al dipartimento di pediatria del Samsung Medical Center.<\/p>
Il medico è un ematologo-oncologo altamente esperto con oltre 26 anni di esperienza nel campo. Specializzato nel trattamento del cancro del colon, dell'oncologia ematologica, dei mielomi e dei linfomi, il medico è competente in procedure avanzate come il trapianto di midollo osseo, inclusi i trapianti da donatori alternativi e non compatibili.<\/p>
Con un forte background accademico, il medico possiede un M.D. dal College of Medicine dell'Università Yonsei e un Ph.D. dal College of Medicine dell'Università Sungkyunkwan. Il medico è anche membro di numerose società professionali e ha contribuito al campo attraverso numerose pubblicazioni di articoli.<\/p>
South Korean medical centers treat severe aplastic anemia with hematopoietic stem cell transplantation (HSCT) and intensive immunosuppressive therapy (IST). Younger patients often receive allogeneic bone marrow transplantation from matched siblings. Older patients or those without donors utilize drug regimens combining antithymocyte globulin with cyclosporine and eltrombopag.
Bookimed Expert Insight: Korea's infrastructure is uniquely suited for complex hematology due to its high-volume digitalized centers. Asan Medical Center alone performs over 65,000 operations annually and maintains a 90% success rate in organ transplants. This volume translates to highly refined protocols for preventing infections during the vulnerable weeks following bone marrow replacement.
Patient Consensus: Patients note it's important to start HLA testing immediately because Korea's donor registry is highly efficient. Many emphasize the need to arrange long-term housing near the hospital for the 3-to-6 month recovery period.
South Korea manages the horse ATG shortage by using rabbit-derived anti-thymocyte globulin as the primary immunosuppressive therapy. Hospitals combine rabbit ATG with cyclosporine and methylprednisolone. Major centers also integrate eltrombopag to improve blood cell counts. Bone marrow transplantation serves as the definitive curative alternative.
Bookimed Expert Insight: Korea's heavy investment in digital infrastructure at centers like Seoul National University Bundang Hospital ensures precise long-term monitoring. Since over 50% of Korean patients require more than one year to respond to rabbit ATG, these digital tracking systems are vital for adjusting therapy. Hospitals like Asan Medical Center, performing over 65,000 surgeries annually, often transition patients to transplant quickly if immunosuppression doesn't show early promise.
Patient Consensus: Patients note it is important to prepare for a longer medical journey than expected. Practical focus often shifts toward finding specialized hematologists in Seoul who can manage the extended follow-up care required for rabbit-based regimens.
Korean medical centers report a 95% 5-year overall survival rate for severe aplastic anemia using bone marrow transplantation. This success rate applies to patients receiving tissue from HLA-identical sibling donors. These outcomes exceed survival rates of 70% typically observed with immunosuppressive therapy protocols.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. This high volume allows for ultra-specialization in complex donor matching and conditioning. Our data shows that centers with these certifications maintain consistency in 5-year survival reporting.
Patient Consensus: Visitors suggest that the administrative speed in Seoul helps reduce wait times for transplant. Many note that clear communication about donor compatibility from the start reduces stress during recovery.
Korean hospitals are highly prepared for international aplastic anemia patients. Major centers like Samsung Medical Center provide dedicated international departments with coordinators and translators. These facilities combine high transplantation volumes with Joint Commission International accreditation to ensure safety for foreign nationals seeking complex hematologic care.
Bookimed Expert Insight: The data shows a powerful link between high patient volume and successful outcomes in Seoul. Asan Medical Center manages over 10,000 daily outpatients and handles nearly half of the nation's transplants. This massive clinical experience often leads to improved protocols and lower rejection rates for complex aplastic anemia cases.
Patient Consensus: Patients highlight that using hospital international desks helps prevent most logistical issues. They also recommend preparing medical record translations early to avoid delays in starting treatment after arrival.
International patients should plan for a 90-day stay in South Korea for a bone marrow transplant. This timeframe covers a 7-day diagnostic phase and 3 to 6 weeks of sterile hospitalization. Patients must remain near the hospital for 60 days of post-discharge monitoring to manage recovery.
Bookimed Expert Insight: While major centers like Asan Medical Center and Samsung Medical Center serve over 2,000,000 patients yearly, their high volume means isolation beds are tightly scheduled. If you miss your conditioning window, you might wait weeks for the next available sterile bed. Always confirm your bed reservation before booking flights, as these facilities maintain nearly 100% occupancy for transplant units.
Patient Consensus: Patients note it is vital to secure housing within 15 minutes of the hospital because post-discharge fatigue makes even short trips difficult. They also suggest planning for a 4 to 6-month stay to account for the slow recovery of the immune system.
Bone marrow transplants for severe aplastic anaemia in South Korea show a 95% five-year survival rate for patients with matched sibling donors. Centres such as Samsung Medical Center and Severance Hospital use modern haploidentical techniques. These methods achieve success rates reaching 90% even without perfectly matched donors.
Bookimed Expert Insight: South Korea's transplant landscape is defined by digital integration. Centres like Seoul National University Bundang Hospital use the BESTcare system to reduce medical errors. This digital infrastructure supports high-volume transplant units at Asan Medical Center. Asan handles 180,000+ patients annually and reports organ transplant success rates from 90%.
Patient Consensus: Patients highlight that results depend heavily on finding a matched sibling donor. They advise checking specific survival data for their exact age group and donor type in Korea.
Seoul St. Mary's Hospital and Asan Medical Center lead South Korea in treating aplastic anaemia. These centres provide haematology services and stem cell transplantation. Other specialist facilities include Samsung Medical Center and Seoul National University Hospital. Most are JCI-accredited and hold KOIHA certification.
Bookimed Expert Insight: Samsung Medical Center serves over 2 million patients annually. The Newsweek World's Best Hospitals list includes them for their complex case capacity. Large centres like this or Asan Medical Center offer integrated diagnostic methods. This includes cytogenetic bone marrow analysis and genetic screening within one facility.
Patient Consensus: Patients note that major tertiary centres in Seoul offer better access to beds. This includes bone marrow transplant beds and more donor options. They suggest confirmed English-speaking coordination is essential for managing intensive follow-up care.
South Korea hosts leading specialists for aplastic anaemia, particularly in Seoul-based tertiary centres. Experts such as Prof. Lee Jong-wook at Seoul St. Mary's Hospital and Dr Seung-ah Yahng provide specialised care. These specialists focus on haematopoietic stem cell transplantation and managing bone marrow failure.
Bookimed Expert Insight: Prof. Lee Jong-wook and others are highly sought after. Facilities like Samsung Medical Center and SNUH use digitalised records and telemedicine. This helps Australian patients manage long-term haematology follow-ups and record transfers after returning home.
Patient Consensus: Patients note that care in South Korea is hospital-based. It is essential to bring complete biopsy reports and arrange interpreters before arriving in Seoul.
South Korean medical centres treat refractory or relapsing aplastic anaemia using allogeneic haematopoietic stem cell transplantation (HSCT) and specialised pharmacological agents. Specialists prioritise unrelated or haploidentical transplants within six months of initial treatment failure. JCI-accredited hospitals in Seoul add eltrombopag to standard salvage protocols to improve patient outcomes.
Bookimed Expert Insight: Many countries focus solely on matched donors. However, South Korean centres like Seoul National University Hospital specialise in haploidentical transplants. These facilities serve over 10,000 patients daily and use the BESTcare digital system. This high volume allows doctors to perfect mismatched donor protocols. These procedures are often less available in Australia.
Patient Consensus: Patients often highlight the speed of diagnosis in South Korea. This process involves bone marrow biopsies and genetic screening. They note that digital health records at major Seoul hospitals help manage complex transplant recovery.
Patients can usually start a stem cell transplant within 1 week of arriving in the Republic of Korea. Specialists at centres like Samsung Medical Center complete diagnostic tests and donor matching in about 7 days. Most patients stay 3 months for monitoring.
Bookimed Expert Insight: Samsung Medical Center and Asan Medical Center handle massive patient volumes, serving over 180,000 people annually. This high throughput allows these Seoul-based facilities to offer fast-tracked HLA testing. Their digitalised BESTcare systems further reduce administrative delays during donor registry searches.
Patient Consensus: Patients note that donor source strongly affects wait times in South Korea. They suggest starting HLA typing early to avoid delays if a family match isn't available.